Last reviewed 2026-04-20 · How we verify

Lyumjev

Lyumjev, developed by the McGill University Health Centre and its Research Institute, is a marketed drug primarily indicated for Type 1 diabetes mellitus. A key strength of Lyumjev is its unique mechanism, which differentiates it in the diabetes treatment landscape. The primary risk is the expiration of its key composition patent in 2028, potentially leading to increased competition from generics.

At a glance

Approved indications

• Diabetes mellitus type 1
• Diabetes mellitus type 2

Common side effects

• Hypoglycemia
• Injection/infusion site reactions
• Weight gain
• Lipodystrophy
• Pruritus
• Rash

Serious adverse events

• Severe hypoglycemia
• Anaphylaxis
• Angioedema
• Bronchospasm
• Hypotension
• Shock
• Generalized skin reactions

Key clinical trials

• Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (NA)
• Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes (NA)
• A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500 (PHASE1)
• Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (PHASE1)
• A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (PHASE4)
• Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes (PHASE1, PHASE2)
• Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® (NA)
• Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.